Anti-Glutamate Receptor NMDAR2A (NR2A) antibody produced in rabbit

Applications in which this antibody has been used successfully, and the associated peer-reviewed papers, are given below.
Western Blotting (1 paper)

Rabbit polyclonal anti-Glutamate Receptor NMDAR2A (NR2A) antibody is used to tag the 180 kDa NR2A subunit of the NMDA receptor for detection and quantitation by immunocytochemical and immunohistochemical (IHC) techniques such as immunoblotting and immunoprecipitation. It is used as a probe to determine the presence and roles of the 180 kDa NR2A subunit in the assembly and function of N-Methyl-D-Aspartate (NMDA) receptor complexes.

Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.

Rabbit polyclonal anti-Glutamate Receptor NMDAR2A (NR2A) antibody labels the 180 kDa NR2A subunit of the NMDA receptor. This labeling is blocked by the preadsorption of the antibody with the immunogen. The antibody does not cross-react with the NR2B or NR2C subunits. It reacts with rat, mouse and human tissues.

The N-Methyl-D-Aspartate (NMDA) receptor complex is comprised of 2 types of subunits, NR1 and NR2. Only one type of NR1 subunits has yet been identified while four distinct subunits have been identified for the NR2 receptor, NR2A, NR2B, NR2C, and NR2D. While the NR2 subunits are not functional alone, they combine with the NR1 subunit to produce a variety of different receptor types. A number have studies have also shown that the functional properties of the receptors complexes formed by the NR1 and NR2 subunits are largely determined by the NR2 components of the complex. NMDA receptors are post-synaptic and play important roles in plasticity in the developing and mature central nervous system (CNS). Agonists and antagonists of NMDA receptors have been proposed to be of therapeutic benefit in a number of CNS disorders, including stroke, head injury, epilepsy, pain, and Alzheimer′s disease.

C-terminal portion of NR2A (amino acids 1253-1391).

Lyophilized from ammonium bicarbonate (5 mM)